Review
Oncology
Brian M. Lam, Clare Verrill
Summary: Breast cancer is a common and deadly disease among women worldwide. The field of onco-immunology has not produced impressive results in breast cancer, and research has focused mainly on T lymphocytes, neglecting the potential importance of B lymphocytes. This review aims to evaluate the clinical significance of tumour-infiltrating B lymphocytes in breast cancer and explore future research directions.
Review
Oncology
Melani Luque, Marta Sanz-Alvarez, Miriam Morales-Gallego, Juan Madoz-Gurpide, Sandra Zazo, Carolina Dominguez, Alicia Cazorla, Yann Izarzugaza, Juan Luis Arranz, Ion Cristobal, Federico Rojo
Summary: The immune system plays an important role in breast cancer, and tumor-infiltrating lymphocytes (TILs) predict the response to anti-HER2 therapy. The goal is to enhance the patient's immune system for more effective cancer cell killing. However, the effects of immune cells depend on their infiltration in tumors and the communication with tumor cells.
Article
Oncology
Jenny Pousette, Annelie Johansson, Carolin Jonsson, Tommy Fornander, Linda S. Lindstrom, Hans Olsson, Gizeh Perez-Tenorio
Summary: The presence of immune cells within the tumor (TILs) does not have prognostic value for hormone-responsive breast cancer (ER+/HER2-). However, high expression of certain TIL markers indicates good prognosis and may be used for immunotherapy interventions after tamoxifen failure for ER+/HER2- subtype.
Article
Oncology
Sara Valpione, Luca G. Campana, John Weightman, Zena Salih, Elena Galvani, Piyushkumar A. Mundra, Francesco De Rosa, Avinash Gupta, Patricio Serra-Bellver, Paul Lorigan, Theodora Germetaki, Marek Dynowski, Stephen Kitcatt, Sudhakar Sahoo, Dave Lee, Nathalie Dhomen, Graham Lord, Richard Marais
Summary: This study explored the role of different immune cell subsets in anti-tumor responses to checkpoint inhibitors. It found that B cells play a crucial role in clinical response and may contribute to anti-tumor immunity through antigen presentation. Additionally, the abundance of tumor-infiltrating B cell clonotypes at baseline can identify distinct risk groups and serve as a promising prognostic biomarker for clinical risk stratification.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Italo Fernandes, Anderson Scorsato, Rafael Kaliks, Marcus Corpa, Eduarda Damasceno, Gustavo Schvartsman
Summary: This study aimed to investigate the levels of tumor-infiltrating lymphocytes (TIL) in HER2-low tumors and its correlation with other clinicopathologic features. The results showed that TIL levels in HER2-low tumors are marginally higher than HER2-negative tumors but significantly lower than HER2-positive tumors, indicating that HER2-low tumors do not significantly differ biologically from HER2-negative tumors.
CLINICAL BREAST CANCER
(2023)
Article
Oncology
Teng Sun, Tong Wang, Xiangjun Li, Haibo Wang, Yan Mao
Summary: This study aimed to assess the prognosis of HER2-low-positive breast cancer in Chinese women and the predictive role of tumor-infiltrating lymphocytes (TILs). The results showed that high levels of TILs in HER2-low-positive breast cancer patients were associated with improved disease-free survival (DFS), especially in the HR (+)/HER2-low-positive subtype.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Maschenka C. A. Balkenhol, Francesco Ciompi, Zaneta Swiderska-Chadaj, Rob van de Loo, Milad Intezar, Irene Otte-Holler, Daan Geijs, Johannes Lotz, Nick Weiss, Thomas de Bel, Geert Litjens, Peter Bult, Jeroen A. W. M. van der Laak
Summary: In this study, using multiplex immunohistochemistry and advanced image analysis algorithms, it was found that high density of positive lymphocytes correlated with improved survival in TNBC patients. No significant differences were observed between the results of TILs assessment in different regions. These findings provide insights for optimizing TILs assessment methodology.
Article
Oncology
Laura C. Kennedy, Anum S. Kazerouni, Bonny Chau, Debosmita Biswas, Rebeca Alvarez, Grace Durenberger, Suzanne M. Dintzis, Sasha E. Stanton, Savannah C. Partridge, Vijayakrishna Gadi
Summary: Breast magnetic resonance imaging (MRI) shows promise as an early marker for predicting immune response to treatment in HER2+ breast cancer patients. Functional diffusion-weighted and dynamic contrast-enhanced MRI measures were compared with tumor-infiltrating lymphocytes and RNA immune signature scores, and found to be associated with immune-activated tumor microenvironments.
Article
Medicine, General & Internal
Kathleen Schueler, Daniel Bethmann, Sandy Kaufhold, Carolin Hartung, Kathrin Stueckrath, Tilmann Lantzsch, Christoph Uleer, Volker Hanf, Susanne Peschel, Jutta John, Marleen Poehler, Jorg Buchmann, Karl-Friedrich Buerrig, Edith Weigert, Christoph Thomssen, Eva Johanna Kantelhardt, Martina Vetter
Summary: Tumour-infiltrating lymphocytes (TILs) have prognostic and predictive value for patients with early breast cancer, especially in HER2-positive breast cancer. The distribution of TILs varies among different breast cancer types, and the percentage of TILs is associated with improved prognosis.
Article
Medicine, General & Internal
Zi-An Xia, Can Lu, Can Pan, Jia Li, Jun Li, Yitao Mao, Lunquan Sun, Jiang He
Summary: This study identified two subtypes of tumour-infiltrating lymphocytes (TILs) in breast cancer, CD103(+)LAG3(+) T cells and B cells, and developed a prognostic model (CLTRP) based on the expression profiles of marker genes in these subtypes. The CLTRP score was found to be associated with prognosis, drug sensitivity, molecular and immune characteristics, and immunotherapy outcomes in breast cancer patients.
Review
Oncology
Rafael Caparica, Marco Bruzzone, Elisa Agostinetto, Maria Alice Franzoi, Marcello Ceppi, Nina Radosevic-Robin, Frederique Penault-Llorca, Karen Willard-Gallo, Sherene Loi, Roberto Salgado, Evandro de Azambuja
Summary: High-TIL levels in non-invasive breast cancer are associated with an increased likelihood of local recurrence, but a decreased likelihood of invasive local recurrence. They are also associated with aggressive tumor subtypes, high grade, and necrosis.
Article
Oncology
Yasufumi Sato, Masafumi Shimoda, Yoshiaki Sota, Tomohiro Miyake, Tomonori Tanei, Naofumi Kagara, Yasuto Naoi, Seung Jin Kim, Shinzaburo Noguchi, Kenzo Shimazu
Summary: Humoral immunity plays a significant role in suppressing breast cancer, with a high serum concentration of anti-HER2 autoantibody (HER2-AAb) associated with favorable outcomes in patients. The high level of HER2-AAb is linked to enhanced humoral immunity against breast cancer and may provide a rationale for the favorable prognosis in breast cancer patients.
Review
Oncology
You Qin, Fei Peng, Lisha Ai, Shidai Mu, Yuting Li, Chensu Yang, Yu Hu
Summary: The meta-analysis shows that a high level of TIL-Bs is associated with longer overall survival, breast cancer-specific survival, and disease-free/relapse-free survival in breast cancer patients. This suggests that TIL-Bs could serve as a promising prognostic marker for breast cancer, and may lead to the development of novel therapeutic strategies by enhancing B cell-mediated antitumor immunity.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Zhenzhen Liu, Chengzheng Wang, Xiuchun Chen, Jiujun Zhu, Xianfu Sun, Qingxin Xia, Zhenduo Lu, Jianghua Qiao, Yong Zhou, Haixue Wang, Yi Wang, Min Yan
Summary: This study evaluated the efficacy of pyrotinib plus trastuzumab, docetaxel, and carboplatin as neoadjuvant therapy for early breast cancer and explored the predictive role of immune cell subpopulations. The results showed promising efficacy and manageable toxicity of this treatment regimen. The study also found that the immune microenvironment may play an important role in the response to neoadjuvant pyrotinib-based therapy.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wen-jie Tang, Qing-cong Kong, Zi-xuan Cheng, Yun-shi Liang, Zhe Jin, Lei-xin Chen, Wen-ke Hu, Ying-ying Liang, Xin-hua Wei, Yuan Guo, Xin-qing Jiang
Summary: This study investigated the effect of imaging features at different DCE-MRI phases on predicting TIL levels in breast cancer. Results showed that image features from delayed phase MRI had the best predictive performance, and the fusion multi-sequence radiomics model and combined radiomics-based clinical model performed the best in predicting TILs.
EUROPEAN RADIOLOGY
(2022)
Article
Oncology
Laura Sala, Stefano Bonomi, Alessandra Fabbri, Chiara Maura Ciniselli, Annalisa Bardelli, Paolo Verderio, Giancarlo Pruneri, Umberto Cortinovis
Summary: This study investigated the use of the PEAK PlasmaBlade and acellular dermal matrix Veritas in implant-based breast reconstruction in the setting of radiotherapy. The results showed that this approach could lead to lower complication rates and higher levels of patient and surgeon satisfaction.
Article
Oncology
C. Sessa, J. Balmana, S. L. Bober, M. J. Cardoso, N. Colombo, G. Curigliano, S. M. Domchek, D. G. Evans, D. Fischerova, N. Harbeck, C. Kuhl, B. Lemley, E. Levy-Lahad, M. Lambertini, J. A. Ledermann, S. Loibl, K. -A. Phillips, S. Paluch-Shimon
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
G. Spitaleri, P. Trillo Aliaga, C. Catania, E. Del Signore, I. Attili, C. Santoro, F. Giugliano, P. P. M. Berton Giachetti, G. . Curigliano, A. Passaro, F. de Marinis
Summary: This prospective trial examined the safety of COVID-19 vaccines in patients with thoracic cancer receiving anticancer treatments. The results showed no safety concerns and a low rate of vaccine-related adverse events. The study supports prioritizing vaccination for lung cancer patients undergoing active treatment.
CLINICAL LUNG CANCER
(2023)
Article
Oncology
Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escriva-de-Romani, Michelino De Laurentiis, Gary N. Schwartz, Timothy J. Pluard, Francesco Ricci, William R. Gwin II, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarina Petrakova, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar
Summary: Clinical trials often report initial results based on the primary end point, while additional results from secondary analyses may not be available. In this study comparing margetuximab and trastuzumab in breast cancer patients, the final overall survival analysis did not show an advantage of margetuximab over trastuzumab. However, exploratory analysis suggested potential improvements in specific patient groups based on CD16A genotyping.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Sara A. Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, Jose Manuel Perez-Garcia, Sung-Bae Kim, Vanessa Petry, Chiun-Sheng Huang, Wei Li, Jean-Sebastien Frenel, Silvia Antolin, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortes
Summary: In the DESTINY-Breast03 trial, trastuzumab deruxtecan showed superior progression-free survival compared to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. The study aimed to compare the efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine. The results demonstrated that trastuzumab deruxtecan had the longest reported median progression-free survival and improved overall survival, reaffirming its role as the standard of care in the second-line setting.
Review
Oncology
Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano
Summary: Phosphoinositide 3-kinases (PI3Ks) play a crucial role in tumorigenesis, particularly the p110 alpha subunit (PIK3CA) with activating mutations found in various tumors. Current PI3K inhibitors have limited efficacy due to on-target toxicity, inhibiting both wild-type and mutant PI3Ks. However, the development of mutant and isoform selective PIK3CA inhibitors has surged interest in targeting PIK3CA in solid tumors. This review summarizes the understanding of PI3K alterations, treatment strategies, and emerging resistance mechanisms and the role of mutant selective PIK3CA inhibitors.
BRITISH JOURNAL OF CANCER
(2023)
Review
Oncology
Chiara Corti, Federica Giugliano, Eleonora Nicolo, Paolo Tarantino, Carmen Criscitiello, Giuseppe Curigliano
Summary: Breast cancer is divided into three main groups: hormone receptor-positive HER2-negative, HER2-positive, and triple-negative BC. Technological breakthroughs have allowed for the development of antibody-drug conjugates (ADCs) as a treatment option. Even with low HER2 receptor expression, the use of T-DXd may provide clinical benefit for HER2-positive breast cancer. In HR-negative HER2-low subtype, the use of T-DXd is justified despite limited evidence, considering the poor prognosis of TNBC.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Oncology
Pamela Trillo, Jose Sandoval, Dario Trapani, Eleonora Nicolo, Paola Zagami, Federica Giugliano, Paolo Tarantino, Grazia Vivanet, Liliana Ascione, Alex Friedlaender, Angela Esposito, Carmen Criscitiello, Giuseppe Curigliano
Summary: The study retrospectively analyzed data of patients with recurrent invasive lobular carcinoma (ILC) and found discordance in the expression of ER, PgR, and HER2 between primary tumors and metastases. These findings suggest that phenotypic switch during metastasis may have implications for treatment decisions and prognosis in patients with ILC.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Genetics & Heredity
Mariia Ivanova, Francesca Maria Porta, Federica Giugliano, Chiara Frascarelli, Elham Sajjadi, Konstantinos Venetis, Giulia Cursano, Giovanni Mazzarol, Elena Guerini-Rocco, Giuseppe Curigliano, Carmen Criscitiello, Nicola Fusco
Summary: Breast cancer is a widely prevalent and deadly malignancy, with brain metastases being a significant contributor to mortality. The formation, progression, and colonization of primary breast tumors and subsequent brain metastases involve diverse molecular pathways, which complicates their clinical management. Despite advancements in primary breast cancer treatments, the prognosis for patients with brain metastases remains poor. This review aims to highlight the biological mechanisms of breast cancer brain metastases and discuss available and emerging treatment strategies for managing this complex disease.
Review
Oncology
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, Carmine Valenza, Giuseppe Curigliano
Summary: HER2-positive metastatic breast cancer is a subtype of breast cancer with aggressive behavior and sensitivity to HER2-targeted agents. Antibody-drug conjugates (ADCs), such as T-DM1 and T-DXd, have shown improved clinical outcomes in this subtype. However, resistance to these ADCs still occurs, highlighting the need for understanding the underlying mechanisms.
Review
Oncology
Federica Giugliano, Ambra Carnevale Schianca, Chiara Corti, Mariia Ivanova, Nadia Bianco, Silvia Dellapasqua, Carmen Criscitiello, Nicola Fusco, Giuseppe Curigliano, Elisabetta Munzone
Summary: Breast cancer is common and approximately 15% are HER2-positive. HER2 protein expression can be heterogeneous, affecting treatment choices. Novel pharmacological agents, such as antibody-drug conjugates, may help overcome this issue.
Review
Cell Biology
Gabriele Antonarelli, Valentina Pieri, Francesca Maria Porta, Nicola Fusco, Gaetano Finocchiaro, Giuseppe Curigliano, Carmen Criscitiello
Summary: Various tumors rely on post-translational modifications to promote invasiveness, angiogenesis, and reprogram cellular energetics. Fucosylation, a type of glycosylation, has been linked to immune and hormonal functions as well as tumor development. In breast cancer, fucosylation of the glycan core is associated with poor prognosis and increased metastatic potential. Pre-clinical studies have investigated the molecular mechanisms of core-fucosylation in breast cancer models and its potential as a biomarker for predicting cancer outcomes.
Article
Oncology
Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fuca, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Summary: In 428 patients with HR+/HER2- advanced breast cancer, HER2-low status was found to be independently associated with worse progression-free survival (PFS) and overall survival (OS) compared to HER2-0 status. These findings suggest that HER2-low status could serve as a new prognostic biomarker in this clinical setting.
Review
Oncology
Carmine Valenza, Beatrice Taurelli Salimbeni, Celeste Santoro, Dario Trapani, Gabriele Antonarelli, Giuseppe Curigliano
Summary: Tumor-infiltrating lymphocytes (TILs) are a potential biomarker with prognostic and predictive potential in breast cancer. They have been shown to have higher treatment response and improved survival outcomes in early triple-negative breast cancer. However, the clinical use of TILs as biomarkers is limited by the lack of rigorous validation. This review discusses the current issues and future challenges in assessing and validating TILs as predictive and prognostic biomarkers in breast cancer.
Review
Oncology
Eleonora Nicolo, Luca Boscolo Bielo, Giuseppe Curigliano, Paolo Tarantino
Summary: HER2-low expression is an essential biomarker for treatment selection in breast cancer, and recent clinical trials have shown promising results with novel HER2-targeted therapies. It is important to develop more sensitive and reliable methods for HER2 testing and scoring to accurately identify patients who may benefit from these treatments.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
